Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease: 18F-Florbetaben Positron Emission Tomography Study
Authors not listed
Judit Pich Martínez · 2015
Abstract
The main purpose of the study is to assess safety of a single dose of FBB followed by PET scan in individuals at risk of genetic Alzheimer's disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2015). Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease: 18F-Florbetaben Positron Emission Tomography Study. <em>Judit Pich Martínez</em>. https://clinicaltrials.gov/study/NCT02362880
Vancouver
Anonymous. Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease: 18F-Florbetaben Positron Emission Tomography Study. Judit Pich Martínez. 2015.
BibTeX
@misc{anon2015Studyo,
title = {Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease: 18F-Florbetaben Positron Emission Tomography Study},
author = {Anonymous},
journal = {Judit Pich Martínez},
year = {2015},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
National Institute on Aging (NIA) 2004
Open access · US-GOV
Clinical Correlates of Longitudinal PET Changes in Alzheimer's Disease (AD)
The Lancet 2021
Preprint · OA
Alzheimer's disease
Handbook of clinical neurology 2019
Citation only
Alzheimer's disease
Nature Reviews Neurology 2024
Preprint · OA
Is Alzheimer disease a disease?
Florida Atlantic University 2007
Open access · US-GOV
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
New York State Psychiatric Institute 2010
Open access · US-GOV